Showing results (271-280 of 301) with videos related to

Sort By:
Pageof 31
American Journal of Clinical Oncology|December 1, 1995
Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group studyM A Gertz, L A Kalish, R A Kyle, et al.
Cancer|April 15, 1982
Primary anterior mediastinal seminomaR D Hurt, J E Bruckman, G M Farrow, et al.
Cancer|January 15, 1989
Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanomaD L Ahmann, E T Creagan, R G Hahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drugD L Ahmann, D J Schaid, H F Bisel, et al.
The New England Journal of Medicine|August 18, 1977
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomyD L Ahmann, M J O'Connell, R G Hahn, et al.
Annals of Internal Medicine|August 1, 1987
Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)L K Kvols, M Buck, C G Moertel, et al.
The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.
American Journal of Clinical Oncology|April 1, 1982
Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancerJ N Ingle, D L Ahmann, S J Green, et al.
Cancer|December 1, 1991
Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy?C M van Haelst-Pisani, J C Buckner, H M Reiman, et al.
Investigational New Drugs|January 1, 1990
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot studyD L Trump, J C Marsh, L K Kvols, et al.
Pageof 31